drugset / Trial / NCT01193621
Early Clinical Evaluation of the Pharmacokinetics and Mechanism Based Pharmacodynamics of Haloperidol Using Positron Emission Tomography in Healthy Volunteers
RandomizedParallel-groupOpen-label
Summary
In the present study, the investigators will establish the clinical trial technology for early evaluation of drug characteristics in terms of pharmacokinetics and pharmacodynamics for haloperidol as a model drug, using positron emission tomography.
Timeline
- Start
- 2008-01
- Primary completion
- 2010-07
- Completion
- 2012-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Haloperidol | Other / unclassified | 0.5 mg | Intravenous |
| Comparator | Haloperidol | Other / unclassified | 1 mg | Intravenous |
| Comparator | Haloperidol | Other / unclassified | 3 mg | Intravenous |
| Comparator | Haloperidol | Other / unclassified | 5 mg | Intravenous |
| Comparator | Haloperidol | Other / unclassified | 370 mbq | Intravenous |
Indications
No indication recorded.